Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 1
2008 1
2009 1
2010 3
2011 3
2012 6
2013 8
2014 10
2015 16
2016 20
2017 17
2018 16
2019 22
2020 26
2021 32
2022 31
2023 28
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
Erkert L, Gamez-Belmonte R, Kabisch M, Schödel L, Patankar JV, Gonzalez-Acera M, Mahapatro M, Bao LL, Plattner C, Kühl AA, Shen J, Serneels L, De Strooper B; TRR241 IBDome Consortium; Neurath MF, Wirtz S, Becker C. Erkert L, et al. Gut. 2024 Apr 29:gutjnl-2023-331622. doi: 10.1136/gutjnl-2023-331622. Online ahead of print. Gut. 2024. PMID: 38684238
Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study.
Suzuki K, Sameshima Y, Yokoyama J, Terai S, Yoneyama H, Atreya R, Neurath MF, Hibi T, Asakura H. Suzuki K, et al. Among authors: atreya r. Inflamm Regen. 2024 Apr 25;44(1):22. doi: 10.1186/s41232-024-00332-7. Inflamm Regen. 2024. PMID: 38664814 Free PMC article.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R. Peyrin-Biroulet L, et al. Among authors: atreya r. BMC Gastroenterol. 2024 Mar 27;24(1):121. doi: 10.1186/s12876-024-03163-5. BMC Gastroenterol. 2024. PMID: 38539103 Free PMC article.
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.
Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath MF, Dörje F, Atreya R. Plechschmidt J, et al. Among authors: atreya r. Inflamm Bowel Dis. 2024 Mar 20:izae040. doi: 10.1093/ibd/izae040. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38507608
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ, Wright J, Watanabe K, Ford S, Remple VP, Lacerda AP, Dubcenco E, Garrison A, Zhou Q, Berg S, Anyanwu SI, Schreiber S. Peyrin-Biroulet L, et al. Among authors: atreya r. Clin Gastroenterol Hepatol. 2024 Mar 15:S1542-3565(24)00253-2. doi: 10.1016/j.cgh.2024.02.026. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38492904 Free article.
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, Ford S, Remple VP, Lacerda AP, Anyanwu SI, Mallick M, Garrison A, Regueiro M. Colombel JF, et al. Among authors: atreya r. Clin Gastroenterol Hepatol. 2024 Mar 15:S1542-3565(24)00254-4. doi: 10.1016/j.cgh.2024.02.027. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38492903 Free article.
Biomarkers for Personalizing IBD Therapy: The Quest Continues.
Atreya R, Neurath MF. Atreya R, et al. Clin Gastroenterol Hepatol. 2024 Feb 4:S1542-3565(24)00104-6. doi: 10.1016/j.cgh.2024.01.026. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38320679 Free article. Review.
Blocking GPR15 counteracts integrin-dependent T cell gut homing in vivo.
Schramm S, Liu LJ, Saad M, Dietz L, Dedden M, Müller TM, Atreya I, Voskens CJ, Atreya R, Neurath MF, Zundler S. Schramm S, et al. Among authors: atreya r. J Crohns Colitis. 2024 Jan 18:jjae012. doi: 10.1093/ecco-jcc/jjae012. Online ahead of print. J Crohns Colitis. 2024. PMID: 38243565
225 results